Founded by Flagship Pioneering, Cellarity is the first company developing medicines through an understanding of cell behaviors. The company’s broad platform harnesses single-cell technologies and machine learning to digitize and quantify cellular behaviors, unravel the network dynamics that govern those behaviors, and generate medicines that can direct them. Cellarity is using its platform to design medicines targeting the full cellular and molecular complexity of disease, enabling a quantum leap in the success rate and speed of drug discovery.
Location: United States, Massachusetts, Cambridge
Employees: 51-200
Total raised: $121M
Founded date: 2017
Investors 1
| Date | Name | Website |
| 26.02.2021 | Ahren Inno... | ahreninnov... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 04.10.2022 | Series C | $121M | - |
Mentions in press and media 8
| Date | Title | Description |
| 15.10.2025 | Nilo Therapeutics Secures $101M for Neuro-Immunology Revolution | Nilo Therapeutics launched with $101 million Series A funding. The neuro-immunology biotech seeks to restore immune balance. It modulates neural circuits, targeting autoimmune and inflammatory diseases. Key investors include The Column Grou... |
| 08.10.2025 | Immunology biotech Nilo launches with $101M and mission to harness neural circuits | Nilo Therapeutics has launched with $101 million in series A funds to drive its ambition to harness neural circuits to restore immune homeostasis. The New York-headquartered company was founded by a trio of respected academics in Columbia U... |
| 10.01.2023 | The billionaire CEO of a top biotech VC firm details how a new type of AI could transform how we test and discover treatments | Flagship Pioneering CEO Noubar Afeyan. Flagship Pioneering Artificial intelligence has the power to revolutionize biotech, Noubar Afeyan says. Afeyan is the CEO and founder of Flagship Pioneering, the venture firm behind Moderna. Flagship h... |
| 07.11.2022 | Class of 2023 | From day one, Contrary’s mission has been to identify the brightest, scrappiest, and most talented builders in the world, and support them for life. Alongside many other initiatives, we do this with our community - and for the past 6 years,... |
| 04.10.2022 | Flagship-founded Cellarity tacks on $121M series C to fund cell behaviour pipeline | Flagship-founded Cellarity has hauled in $121 million in new series C funds as the biotech continues to push its cell behavior therapies toward the clinic. The latest financing round, announced Tuesday, brings the company’s total raised to ... |
| 04.10.2022 | Cellarity Closes $121M Series C Financing | Cellarity, a Somerville, MA-based life sciences company, raised $121M in Series C funding. The round, which brought total funding raised to date to $274m, was led by Flagship Pioneering with participation from Kyowa Kirin and Hanwha Impact ... |
| 25.02.2021 | Cellarity nets $123M to drive cell behavior pipeline toward clinic | New approach to drug design, check. New CEO, check. Now, Cellarity is raising $123 million in venture capital to propel multiple programs targeting cell behavior toward the clinic and keep improving the technology that underlies those asset... |
| - | Cellarity | “Cellarity ” |